Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02309333 · ClinicalTrials.gov registry record
Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database
A clinical trial, sponsored by Emory University.
- Terminated
- Registry status
- 117
- Enrollment target
NCT02309333 is a clinical trial that was terminated before completion, run by Emory University. The registered enrollment target is 117 participants.
The verdict
NCT02309333 was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- 117 participants
- Enrollment target
Study Summary
Acute promyelocytic leukemia (APL) is a very rare type of leukemia. Because it is so rare, many doctors do not have experience treating it. APL has been shown to be curable most of the time. Unfortunately, some patients die early after they become sick with APL, sometimes even before starting treatment. The early period is from the time of diagnosis through the first treatments for the disease. This is approximately 30 days. Early deaths are often due to complications caused by of the effects of leukemia and the treatments of it. These complications may not be noticed quickly by doctors who don't have much experience with managing APL. The purpose of this study is to collect information about the diagnosis and management of APL patients by review of their medical records. This information will be stored in a central database at Emory University. This data will be analyzed to discover the impact of increased physician knowledge of recommended management of APL. The goal is to reduce the events of early death of APL patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02309333
The ClinicalTrials.gov registry entry for NCT02309333 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02309333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02309333 about?
NCT02309333 is a clinical study titled "Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database". Acute promyelocytic leukemia (APL) is a very rare type of leukemia. Because it is so rare, many doctors do not have experience treating it. APL has been shown to be curable most of the time. Unfortunately, some patients die early after they become sick with APL, sometimes even before starting treatm...
What is the current status of trial NCT02309333?
This trial is currently terminated. The enrollment target is 117 participants. The study started on 2014-11. Estimated completion is 2018-09.
Who is sponsoring clinical trial NCT02309333?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.